DE69633940T2 - Verfahren zur isolierung von zellen - Google Patents
Verfahren zur isolierung von zellen Download PDFInfo
- Publication number
- DE69633940T2 DE69633940T2 DE69633940T DE69633940T DE69633940T2 DE 69633940 T2 DE69633940 T2 DE 69633940T2 DE 69633940 T DE69633940 T DE 69633940T DE 69633940 T DE69633940 T DE 69633940T DE 69633940 T2 DE69633940 T2 DE 69633940T2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- stool
- chair
- dna
- die
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 239000011324 bead Substances 0.000 claims abstract description 50
- 238000007710 freezing Methods 0.000 claims abstract description 20
- 230000008014 freezing Effects 0.000 claims abstract description 20
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 12
- 238000012544 monitoring process Methods 0.000 claims abstract description 11
- 238000001816 cooling Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 155
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- 238000012360 testing method Methods 0.000 claims description 45
- 238000005406 washing Methods 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 42
- 210000002919 epithelial cell Anatomy 0.000 claims description 41
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 28
- 230000005291 magnetic effect Effects 0.000 claims description 25
- 230000002550 fecal effect Effects 0.000 claims description 20
- 210000000981 epithelium Anatomy 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 230000009826 neoplastic cell growth Effects 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 9
- 239000002344 surface layer Substances 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000007790 scraping Methods 0.000 claims description 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 22
- 239000004327 boric acid Substances 0.000 abstract description 22
- 238000003556 assay Methods 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 60
- 239000000243 solution Substances 0.000 description 58
- 239000000725 suspension Substances 0.000 description 51
- 239000000523 sample Substances 0.000 description 33
- 210000003608 fece Anatomy 0.000 description 25
- 239000008188 pellet Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 20
- 238000002955 isolation Methods 0.000 description 19
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 102000005720 Glutathione transferase Human genes 0.000 description 16
- 108010070675 Glutathione transferase Proteins 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 13
- 206010036790 Productive cough Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 210000003802 sputum Anatomy 0.000 description 12
- 208000024794 sputum Diseases 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 208000037062 Polyps Diseases 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 10
- 231100000504 carcinogenesis Toxicity 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- 210000003097 mucus Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 201000010989 colorectal carcinoma Diseases 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 208000005623 Carcinogenesis Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000036952 cancer formation Effects 0.000 description 8
- 231100000357 carcinogen Toxicity 0.000 description 8
- 239000003183 carcinogenic agent Substances 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 7
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 101710113436 GTPase KRas Proteins 0.000 description 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000010794 food waste Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 101100069663 Caenorhabditis elegans gst-1 gene Proteins 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101100449761 Musca domestica Gst1 gene Proteins 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 101100346189 Caenorhabditis elegans mpc-1 gene Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710202061 N-acetyltransferase Proteins 0.000 description 3
- 206010073310 Occupational exposures Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 231100000675 occupational exposure Toxicity 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011049 pearl Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102100038108 Arylamine N-acetyltransferase 1 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 108020005124 DNA Adducts Proteins 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000008636 Neoplastic Processes Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000034615 apoptosis-related disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003443 bladder cell Anatomy 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000002375 environmental carcinogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 208000020603 familial colorectal cancer Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 208000022131 polyp of large intestine Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001855 preneoplastic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229910052704 radon Inorganic materials 0.000 description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000006440 Grob fragmentation reaction Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000003632 chemoprophylactic effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011060 control of substances hazardous to health Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020788 dietary exposure Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 208000037958 occupational cancer Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/42—Low-temperature sample treatment, e.g. cryofixation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9518156 | 1995-09-06 | ||
| GBGB9518156.6A GB9518156D0 (en) | 1995-09-06 | 1995-09-06 | Method of isolating cells |
| PCT/GB1996/002177 WO1997009600A2 (en) | 1995-09-06 | 1996-09-05 | Method of isolating cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69633940D1 DE69633940D1 (de) | 2004-12-30 |
| DE69633940T2 true DE69633940T2 (de) | 2005-12-22 |
Family
ID=10780261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69633940T Expired - Fee Related DE69633940T2 (de) | 1995-09-06 | 1996-09-05 | Verfahren zur isolierung von zellen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6187546B1 (https=) |
| EP (1) | EP0873502B1 (https=) |
| JP (1) | JPH11511982A (https=) |
| AT (1) | ATE283473T1 (https=) |
| AU (1) | AU6883096A (https=) |
| DE (1) | DE69633940T2 (https=) |
| GB (1) | GB9518156D0 (https=) |
| WO (1) | WO1997009600A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952178A (en) | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
| GB9705949D0 (en) * | 1997-03-21 | 1997-05-07 | Electrophoretics International | Diagnosis of tumours and other abnormalities of body cells |
| GB9709728D0 (en) * | 1997-05-13 | 1997-07-02 | Dynal As | Single step method |
| US6268136B1 (en) * | 1997-06-16 | 2001-07-31 | Exact Science Corporation | Methods for stool sample preparation |
| AU7816898A (en) * | 1997-06-16 | 1999-01-04 | Exact Laboratories, Inc. | Methods for stool sample preparation |
| EP0939118A1 (en) * | 1998-02-20 | 1999-09-01 | Universiteit Maastricht | Method for isolating DNA and RNA from faeces |
| US6280947B1 (en) | 1999-08-11 | 2001-08-28 | Exact Sciences Corporation | Methods for detecting nucleotide insertion or deletion using primer extension |
| CA2366778C (en) | 1999-04-09 | 2008-07-22 | Exact Sciences Corporation | Methods for detecting nucleic acids indicative of cancer |
| US6534280B1 (en) * | 1999-04-15 | 2003-03-18 | Padmanabhan P. Nair | Noninvasive detection of colorectal cancer and other gastrointestinal pathology |
| US6849403B1 (en) | 1999-09-08 | 2005-02-01 | Exact Sciences Corporation | Apparatus and method for drug screening |
| DE19945947A1 (de) * | 1999-09-24 | 2001-03-29 | Schebo Tech Gmbh | Nachweis des Pyruvatkinase-Isoenzyms |
| US6919174B1 (en) | 1999-12-07 | 2005-07-19 | Exact Sciences Corporation | Methods for disease detection |
| WO2001042781A2 (en) | 1999-12-07 | 2001-06-14 | Exact Sciences Corporation | Supracolonic aerodigestive neoplasm detection |
| FR2815509B1 (fr) * | 2000-10-18 | 2004-07-23 | Swap Com | Systeme d'informations personnalisees sur telephone mobile en utilisant la multidiffusion "cell broadcast", et un logiciel de controle d'acces a bord du telephone, telecommande par l'operateur du service |
| ATE309393T1 (de) * | 2001-09-06 | 2005-11-15 | Adnagen Ag | Verfahren zum qualitativen und/oder quantitativen nachweis von zellen |
| DE10143776A1 (de) * | 2001-09-06 | 2003-04-03 | Adnagen Ag | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs |
| DE10143775A1 (de) * | 2001-09-06 | 2003-04-10 | Adnagen Ag | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Darmkrebs |
| DE10153899B4 (de) * | 2001-11-02 | 2005-11-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und Vorrichtung zur Biosensorik |
| EP1448792A1 (de) * | 2001-11-22 | 2004-08-25 | Adnagen AG | Diagnose-kit, dns-chip sowie verfahren zur diagnostik oder behandlungskontrolle bei hodenkrebs |
| DE10222494A1 (de) * | 2002-05-15 | 2003-11-27 | Europroteome Ag | Verfahren zur parallelen Gewinnung von RNA und Proteinen aus einer Gewebeprobe |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| CN1223680C (zh) * | 2002-12-10 | 2005-10-19 | 清华大学 | 扩增靶细胞或病毒的核酸的方法 |
| JP4033820B2 (ja) * | 2003-07-29 | 2008-01-16 | 株式会社日立製作所 | 細胞回収方法 |
| GB0318702D0 (en) * | 2003-08-08 | 2003-09-10 | Neill Ian O | Method and apparatus for removing cellular material from faecal stools and container for collecting faecal stools |
| NZ545469A (en) * | 2003-09-12 | 2009-11-27 | Biocontrol Systems Inc | Methods, compositions, and kits for the concentration and detection of microorganisms without a separate DNA extraction step |
| WO2006047787A2 (en) | 2004-10-27 | 2006-05-04 | Exact Sciences Corporation | Method for monitoring disease progression or recurrence |
| JP4477474B2 (ja) | 2004-11-15 | 2010-06-09 | 株式会社日立製作所 | 糞便懸濁ろ過用容器 |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| US8114587B2 (en) * | 2005-06-23 | 2012-02-14 | Ambergen, Inc. | Methods for the detection of colorectal cancer |
| US20090011413A1 (en) * | 2005-12-14 | 2009-01-08 | Canon Kabushiki Kaisha | Method for screening colon cancer cells and gene set used for examination of colon cancer |
| JP4850143B2 (ja) * | 2007-08-08 | 2012-01-11 | オリンパス株式会社 | 遠心分離機および遠心分離機を用いた細胞処理装置 |
| JP5566111B2 (ja) | 2007-11-20 | 2014-08-06 | オリンパス株式会社 | Ｒｎａ回収方法 |
| EP2287331A4 (en) * | 2008-05-12 | 2012-01-25 | Olympus Corp | PROCESS FOR PROCESSING EXCREMENTS AND CONTAINERS FOR PROCESSING EXCREMENTS |
| CN101587043B (zh) * | 2008-05-20 | 2013-10-02 | 北京莱尔生物医药科技有限公司 | 从生物体液样本中富集与检测稀有细胞的整合方法 |
| US20110177969A1 (en) * | 2008-10-01 | 2011-07-21 | Cedars-Sinai Medical Center | The role of il17rd and the il23-1l17 pathway in crohn's disease |
| US8348856B1 (en) | 2008-12-16 | 2013-01-08 | Zanetta Malanowska-Stega | Simultaneous multiple method out-patient uterus biopsy device and method |
| WO2011062549A1 (en) * | 2009-11-23 | 2011-05-26 | Johansson, Enar Bernt | Method used in a human or animal faeces sample processing system, and a sample processing system |
| JPWO2012014694A1 (ja) * | 2010-07-26 | 2013-09-12 | オリンパス株式会社 | 糞便由来核酸の合成方法 |
| KR20130108324A (ko) | 2010-09-01 | 2013-10-02 | 가부시키가이샤 바이오마토릿쿠스 겡큐쇼 | 대장직장암 마커에 대한 항체 |
| GB201107466D0 (en) | 2011-05-05 | 2011-06-15 | Loktionov Alexandre | Device and method for non-invasive collection of colorectal mucocellular layer and disease detection |
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| CN106442039B (zh) | 2011-06-19 | 2020-08-07 | 阿博根公司 | 用于样品采集的装置、溶液和方法 |
| CA2941764C (en) | 2014-03-07 | 2023-10-24 | Dna Genotek Inc. | Composition and method for stabilizing nucleic acids in biological samples |
| MX2019006793A (es) | 2016-12-09 | 2019-11-18 | Zanetta Malanowska Stega | Dispositivo, kit y metodos de cepillo para biopsia. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4971905A (en) * | 1987-08-11 | 1990-11-20 | Pacific Northwest Research Foundation | Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of β-1-3N-acetylglucosaminyltransferase |
| JPH05508307A (ja) * | 1990-01-04 | 1993-11-25 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | ヒトの結腸直腸ガンで欠失した遺伝子 |
| GB9107124D0 (en) * | 1991-04-05 | 1991-05-22 | Dynal As | Chemical process |
| WO1993020235A1 (en) * | 1992-04-01 | 1993-10-14 | The Johns Hopkins University School Of Medicine | Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor |
-
1995
- 1995-09-06 GB GBGB9518156.6A patent/GB9518156D0/en active Pending
-
1996
- 1996-09-05 US US09/043,010 patent/US6187546B1/en not_active Expired - Fee Related
- 1996-09-05 DE DE69633940T patent/DE69633940T2/de not_active Expired - Fee Related
- 1996-09-05 JP JP9510974A patent/JPH11511982A/ja not_active Ceased
- 1996-09-05 WO PCT/GB1996/002177 patent/WO1997009600A2/en not_active Ceased
- 1996-09-05 AU AU68830/96A patent/AU6883096A/en not_active Abandoned
- 1996-09-05 EP EP96929416A patent/EP0873502B1/en not_active Expired - Lifetime
- 1996-09-05 AT AT96929416T patent/ATE283473T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU6883096A (en) | 1997-03-27 |
| US6187546B1 (en) | 2001-02-13 |
| EP0873502B1 (en) | 2004-11-24 |
| GB9518156D0 (en) | 1995-11-08 |
| DE69633940D1 (de) | 2004-12-30 |
| JPH11511982A (ja) | 1999-10-19 |
| EP0873502A2 (en) | 1998-10-28 |
| WO1997009600A2 (en) | 1997-03-13 |
| ATE283473T1 (de) | 2004-12-15 |
| WO1997009600A3 (en) | 1997-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69633940T2 (de) | Verfahren zur isolierung von zellen | |
| John et al. | Evaluation of new occult blood tests for detection of colorectal neoplasia | |
| DE60125065T2 (de) | Verfahren zur krebsdetektion mittels verschachtelter ("nested") methylierungsspezifischer pcr | |
| DE69427131T2 (de) | Siebtest zur früherkennung von kolorektalen neoplasien | |
| DE2648458C2 (de) | Verfahren zum Nachweis eines im Serum von Krebspatienten vorkommenden, spezifischen Proteins und Reagenz zur Durchführung dieses Verfahrens | |
| Sakai et al. | Raphides with barbs and grooves in Xanthosoma sagittifolium (Araceae) | |
| CA2158431A1 (en) | Method of gastrointestinal cancer testing | |
| DE19904267A1 (de) | Verfahren zur Anreicherung von Tumorzellen aus einer Körperflüssigkeit und dazu geeigneter Kit | |
| Farrow | Urine cytology in the detection of bladder cancer: a critical approach | |
| Kao et al. | Detection and screening of oral cancer and pre-cancerous lesions | |
| EP1532444B1 (de) | Verfahren zum untersuchen von körperflüssikeiten auf krebszellen sowie entsprechende analysekits | |
| Branfoot | Pathology of the gastro-intestinal tract | |
| EP2783011B1 (en) | Methods for detecting of benign conditions | |
| EP2314677A1 (en) | Method for collection of nucleic acid from fecal sample, method for analysis of nucleic acid, and apparatus for treatment of fecal sample | |
| Varan et al. | Comparison of the methods evaluating post thawing viability of peripheral blood stem cell graft | |
| KR102828676B1 (ko) | 세포 또는 세포핵의 풍부화 방법 | |
| JP2007505609A (ja) | 大腸癌細胞及び／又は大腸癌前駆細胞の非侵襲的早期検出を行うための方法 | |
| Pappenheimer et al. | Certain cytoplasmic inclusions of liver cells | |
| DE69302276T2 (de) | Diagnostische Methode | |
| DE102005052384B4 (de) | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens | |
| Van der Waal et al. | Paraneoplastic pemphigus as the presenting symptom of a lymphoma of the tongue | |
| Hermansen et al. | Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) | |
| DE69725297T2 (de) | Immuno-magnetische zelltrennung zur erkennung von krebsmetastasenbildung-assozierten genen | |
| DE19716346C1 (de) | Verfahren zum Nachweis von Cytokeratinen | |
| JP2002544520A (ja) | 胃癌の危険性を予測および／または診断するための方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |